Effect of FX dialysers on systemic inflammation and quality of life in chronic haemodialysis patients

Blood Purification

Volumn 27, Issue 2, 2009, Pages 187-193

  Boudville, Neil ^a,b   Horner, Marilyn ^b   McEwan, Elizabeth ^b   Lim, Wai H ^b   Mudge, David W ^c   Markus, Hadley E ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Cytokines; Dialysis; Haemodialysis; Inflammation; Quality of life

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEALTH SURVEY; HEMODIALYSIS; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION;

ADULT; AGED; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; QUALITY OF LIFE; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149331869     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000190786     Document Type: Article

References (29)

1. Excell L MS: ANZDATA Registry Report 2004; in Registry, ANZDAT (ed), Adelaide 2005.
2. USRDS 1999 Annual Report; in System, URD (ed): Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999, pp D1-D37.
3. Chauveau P, Nguyen H, Combe C, Chene G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M: Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005;45:565-571.
4. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996;50:566-570.
5. Krane V, Drechsler C, Wanner C: Dyslipidemia, inflammation and dialysis outcomes: what we know now. Curr Opin Nephrol Hypertens 2006;15:566-570.
6. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P: Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 2008;26:291-299.
7. Moe SM, Chen NX: Inflammation and vascular calcification. Blood Purif 2005;23:64-71.
8. Tseke P, Grapsa E, Stamatelopoulos K, Samouilidou E, Rammos G, Papamichael C, Zakopoulos N: Correlations of sialic acid with markers of inflammation, atherosclerosis and cardiovascular events in hemodialysis patients. Blood Purif 2008;26:261-266.
9. Bowry SK: Nano-controlled membrane spinning technology: regulation of pore size, distribution and morphology of a new polysulfone dialysis membrane. Contrib Nephrol, Basel, Karger, 2002, vol 137, pp 85-94.
10. Ronco C, Bowry SK, Brendolan A, Crepaldi C, Soffiati G, Fortunato A, Bordoni V, Granziero A, Torsello G, La Greca G: Hemodialyzer: from macro-design to membrane nanostructure; the case of the FX-class of hemodialyzers. Kidney Int 2002(suppl):126-142.
11. Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C: Results from EuCliD (European Clinical Dialysis Database): impact of shifting treatment modality. Int J Artif Organs 2002;25:1049-1060.
12. Weber C, Stummvoll HK, Passon S, Falkenhagen D: Monocyte activation and humoral immune response to endotoxins in patients receiving on-line hemodiafiltration therapy. Int J Artif Organs 1998;21:335-340.
13. Hays RD KJ, Mapes DL, Coons SJ, Amin N, Carter WB, Kamberg C: Kidney Disease Quality of Life Short Form (KDQOL-SFTM), Version 1.3: A Manual for Use and Scoring. Santa Monica, Rand, 1995.
14. Klemm A, Franke C, Busch M, Muller A, Franke S, Lang D, Passlick-Deetjen J, Stein G: Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products and homocysteine metabolites. Clin Nephrol 2004;61:191-197.
15. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J: Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis pat ients. Nephrol Dial Transplant 2004;19:2570-2575.
16. Kerr PG, Sutherland WH, de Jong S, Vaithalingham I, Williams SM, Walker RJ: The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: a randomized, single-blinded, controlled clinical trial. Am J Kidney Dis 2007;49:533-539.
17. Mudge DW, Rogers R, Hollett P, Law B, Reiger K, Petrie JJ, Price L, Johnson DW, Campbell SB, Isbel NM, Sullivan M, Hawley CM: Randomized trial of FX high-flux versus standard high-flux dialysis for homocysteine clearance. Nephrol Dial Transplant 2005;20:2178-2185.
18. Lonnemann G, Novick D, Rubinstein M, Passlick-Deetjen J, Lang D, Dinarello CA: A switch to high-flux Helixone membranes reverses suppressed interferon-γ production in patients on low-flux dialysis. Blood Purif 2003;21:225-231.
19. Gueler F, Gwinner W, Schiborr C, Martin M, Klos A, Kirsch T, Fiebeler A, Haller H, Fliser D: Biocompatibility parameters of different dialysis membranes assessed during systemic inflammation. Blood Purif 2005;23:196-202.
20. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M: Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-2322.
21. Erten Y, Tulmac M, Derici U, Pasaoglu H, Altok Reis K, Bali M, Arinsoy T, Cengel A, Sindel S: An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients. Ren Fail 2005;27:581-589.
22. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-2379.
23. Rysz J, Banach M, Cialkowska-Rysz A, Stolarek R, Barylski M, Drozdz J, Okonski P: Blood serum levels of IL-2, IL-6, IL-8, TNF-α and IL-1β in patients on maintenance hemodialysis. Cell Mol Immunol 2006;3:151-154.
24. Martola L, Barany P, Stenvinkel P: Why do dialysis patients develop a heart of stone and bone of china? Blood Purif 2005;23:203-210.
25. Ware JE Jr: SF-36 health survey update. Spine 2000;25:3130-3139.
26. Alexander M, Kewalramani R, Agodoa I, Globe D: Association of anemia correction with health-related quality of life in patients not on dialysis. Curr Med Res Opin 2007;23:2997-3008.
27. Mapes DL, Bragg-Gresham JL, Bommer J, Fukuhara S, McKevitt P, Wikstrom B, Lopes AA: Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:54-60.
28. Opatrny K Jr, Krouzzecky A, Polanska K, Mares J, Tomsu M, Bowry SK, Vienken J: Does an alteration of dialyzer design and geometry affect biocompatibility parameters? Hemodial Int 2006;10:201-208.
29. Stefoni S, Coli L, Cianciolo G, Donati G, Ruggeri G, Ramazzotti E, Pohlmeier R, Lang D: Inflammatory response of a new synthetic dialyzer membrane. A randomised crossover comparison between polysulfone and Helixone. Int J Artif Organs 2003;26:26-32.